![Moutih Rafei](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Moutih Rafei
Chief Tech/Sci/R&D Officer at DEFENCE THERAPEUTICS INC.
Net worth: 57 400 $ as of 31/05/2024
Moutih Rafei active positions
Companies | Position | Start | End |
---|---|---|---|
DEFENCE THERAPEUTICS INC. | Director/Board Member | 05/01/2021 | - |
Chief Tech/Sci/R&D Officer | 09/10/2020 | - | |
University of Montréal | Corporate Officer/Principal | - | - |
Career history of Moutih Rafei
Former positions of Moutih Rafei
Companies | Position | Start | End |
---|---|---|---|
IntelliStem Technologies, Inc.
![]() IntelliStem Technologies, Inc. BiotechnologyHealth Technology IntelliStem Technologies, Inc. is a Canadian biotechnology company that specializes in engineering stem cells for the development of next-generation cell therapy products. The private company is based in Toronto, Canada. The company's proprietary cell platforms, including Super Sentinel Cells (SSCs) for cancer therapeutics and IntelliCells for drug discovery and target identification, are genetically engineered. IntelliStem is currently moving into human clinical trials. The company was founded by Riam Shammaa, who has been the CEO since incorporation. | Chief Tech/Sci/R&D Officer | - | 01/08/2023 |
Founder | - | 01/08/2023 |
Training of Moutih Rafei
McGill University | Doctorate Degree |
Statistics
International
Canada | 5 |
Operational
Chief Tech/Sci/R&D Officer | 2 |
Founder | 2 |
Director/Board Member | 1 |
Sectoral
Health Technology | 3 |
Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
DEFENCE THERAPEUTICS INC. | Health Technology |
Private companies | 1 |
---|---|
IntelliStem Technologies, Inc.
![]() IntelliStem Technologies, Inc. BiotechnologyHealth Technology IntelliStem Technologies, Inc. is a Canadian biotechnology company that specializes in engineering stem cells for the development of next-generation cell therapy products. The private company is based in Toronto, Canada. The company's proprietary cell platforms, including Super Sentinel Cells (SSCs) for cancer therapeutics and IntelliCells for drug discovery and target identification, are genetically engineered. IntelliStem is currently moving into human clinical trials. The company was founded by Riam Shammaa, who has been the CEO since incorporation. | Health Technology |
- Stock Market
- Insiders
- Moutih Rafei
- Experience